Dedicated to the discovery and development of treatments for rare CNS Disorders

About

Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science.

Science

Scientific publications can be found here as well as information on Voltage-gated ion channels as therapeutics targets and Kv3 ion channels.

Pipeline

Clinical stage programmes for schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
Mar 08
RT @Instinctif_HLS:Great to see this exciting new collaboration between @AutifonyLtd and @Boehringer announced! https://t.co/Cx8LI319if
reply retweet favorite
Autifony Therapeutic  @AutifonyLtd
Mar 04
Autifony Therapeutics and Boehringer Ingelheim to collaborate on novel ion channel target with potential in multipl… https://t.co/KMvOWVf9o5
reply retweet favorite
Autifony Therapeutic  @AutifonyLtd
Aug 26
Autifony Therapeutics regains rights to clinical stage Kv3 programme https://t.co/rBHjjR7aC0
reply retweet favorite

News & Events

7th May 2021

Autifony presents key efficacy data for AUT00206 from a first-in-patient safety/PK study in patients with schizophrenia at the Schizophrenia International Research Society annual meeting

Find Out More
4th March 2021

Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders

Find Out More

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
Mar 08
RT @Instinctif_HLS:Great to see this exciting new collaboration between @AutifonyLtd and @Boehringer announced! https://t.co/Cx8LI319if
reply retweet favorite
Autifony Therapeutic  @AutifonyLtd
Mar 04
Autifony Therapeutics and Boehringer Ingelheim to collaborate on novel ion channel target with potential in multipl… https://t.co/KMvOWVf9o5
reply retweet favorite
Autifony Therapeutic  @AutifonyLtd
Aug 26
Autifony Therapeutics regains rights to clinical stage Kv3 programme https://t.co/rBHjjR7aC0
reply retweet favorite
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image